ATE386538T1 - Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden - Google Patents

Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden

Info

Publication number
ATE386538T1
ATE386538T1 AT02710762T AT02710762T ATE386538T1 AT E386538 T1 ATE386538 T1 AT E386538T1 AT 02710762 T AT02710762 T AT 02710762T AT 02710762 T AT02710762 T AT 02710762T AT E386538 T1 ATE386538 T1 AT E386538T1
Authority
AT
Austria
Prior art keywords
factor
polypeptides
factor viii
factor vii
combined use
Prior art date
Application number
AT02710762T
Other languages
English (en)
Inventor
Jens Knudsen
Ulla Hedner
Rasmus Roejkjfr
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of ATE386538T1 publication Critical patent/ATE386538T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02710762T 2001-02-05 2002-02-05 Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden ATE386538T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100186 2001-02-05

Publications (1)

Publication Number Publication Date
ATE386538T1 true ATE386538T1 (de) 2008-03-15

Family

ID=8160159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02710762T ATE386538T1 (de) 2001-02-05 2002-02-05 Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden

Country Status (16)

Country Link
US (5) US20030199444A1 (de)
EP (2) EP1359935A1 (de)
JP (2) JP2004517949A (de)
KR (2) KR20030078901A (de)
CN (2) CN1592632A (de)
AT (1) ATE386538T1 (de)
AU (1) AU2002229510A1 (de)
BR (2) BR0207006A (de)
CA (2) CA2437015A1 (de)
DE (1) DE60225118T2 (de)
ES (1) ES2301624T3 (de)
HU (2) HUP0303143A2 (de)
IL (2) IL156842A0 (de)
PL (2) PL365293A1 (de)
RU (2) RU2292909C2 (de)
WO (2) WO2002062377A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
DE60115422T2 (de) * 2000-05-10 2006-08-17 Novo Nordisk Health Care Ag PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CN101486761A (zh) 2000-09-13 2009-07-22 诺沃挪第克健康护理股份公司 人凝血因子vii变体
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
JP4537059B2 (ja) * 2001-09-27 2010-09-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
CN1863908B (zh) 2003-09-09 2010-08-04 诺和诺德医疗保健公司 凝固因子ⅶ多肽
JP5232470B2 (ja) * 2004-05-27 2013-07-10 バクスター・インターナショナル・インコーポレイテッド 硫酸化多糖を用いて出血性疾患を処置するための方法
EP1761274B1 (de) * 2004-06-21 2009-09-02 Novo Nordisk Health Care AG Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ödemerzeugung nach intrazerebraler hämorrhagie (ich)
JP5236952B2 (ja) * 2005-02-28 2013-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 改善された特性を有するｆｘｉｉｉバリアント
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
JP5122562B2 (ja) * 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
WO2008081024A1 (en) * 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
EP1988101A1 (de) * 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
WO2009051717A2 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
EP2244726A2 (de) 2008-01-18 2010-11-03 Novo Nordisk Health Care AG Verwendung von faktor-viia oder faktor-viia-equivalenten zur vorbeugung oder abschwächung der blutungszunahme und/oder ödembildung nach einer intracerebralen blutung (icb) bei einer ausgewählten subpopulation von icb-patienten
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
US20120148557A1 (en) * 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
BR112012004094A2 (pt) * 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
SG181130A1 (en) * 2009-12-06 2012-07-30 Biogen Idec Hemophilia Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011092242A1 (en) * 2010-01-28 2011-08-04 Novo Nordisk Health Care Ag Factor vii fusion polypeptides
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
ES2562421T3 (es) * 2010-10-12 2016-03-04 The Children's Hospital Of Philadelphia Métodos y composiciones para tratar la hemofilia B
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
WO2020051277A1 (en) * 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
EP3833381B1 (de) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550011C2 (de) * 1975-11-07 1982-11-25 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines antihämophilen Mittels
DE2759053A1 (de) * 1977-12-30 1979-07-12 Uhlin Verfahren zum herstellen von genprodukten von plasmid-dns
EP0044343B1 (de) * 1980-01-28 1984-08-22 Baxter Travenol Laboratories, Inc. Prothrombin enthaltende therapeutische zusammensetzungen und verfahren zur herstellung enzymatisch aktiver blutgerinnungsfaktoren aus prothrombin enthaltenden blutfraktionen
US4381119A (en) * 1980-12-17 1983-04-26 Burroughs Corporation Multipart continuous form
US4501731A (en) * 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE60115422T2 (de) * 2000-05-10 2006-08-17 Novo Nordisk Health Care Ag PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
JP2005510515A (ja) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびプロテインｃ阻害剤を含む薬学的組成物
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US20030118580A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and thrombomodulin polypeptides
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides

Also Published As

Publication number Publication date
CA2437015A1 (en) 2002-08-15
HUP0303143A2 (hu) 2003-12-29
PL365293A1 (en) 2004-12-27
RU2311923C2 (ru) 2007-12-10
US20060211621A1 (en) 2006-09-21
US20080075711A1 (en) 2008-03-27
DE60225118T2 (de) 2009-03-05
EP1359935A1 (de) 2003-11-12
CN1499981A (zh) 2004-05-26
US20030199444A1 (en) 2003-10-23
EP1359936B1 (de) 2008-02-20
KR20030088430A (ko) 2003-11-19
IL156842A0 (en) 2004-02-08
ES2301624T3 (es) 2008-07-01
IL156843A0 (en) 2004-02-08
HUP0303130A2 (hu) 2004-01-28
CN1592632A (zh) 2005-03-09
WO2002062377A3 (en) 2003-03-27
RU2003126911A (ru) 2005-02-27
AU2002229510A1 (en) 2002-08-19
RU2003127018A (ru) 2005-03-10
RU2292909C2 (ru) 2007-02-10
BR0207006A (pt) 2004-02-17
US20060276398A1 (en) 2006-12-07
DE60225118D1 (de) 2008-04-03
PL365290A1 (en) 2004-12-27
JP2004517949A (ja) 2004-06-17
BR0207007A (pt) 2004-02-17
WO2002062376A1 (en) 2002-08-15
EP1359936A2 (de) 2003-11-12
WO2002062377A2 (en) 2002-08-15
KR20030078901A (ko) 2003-10-08
CA2436807A1 (en) 2002-08-15
JP2004517950A (ja) 2004-06-17
US20080076702A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
DE60225118D1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
HK1080517A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
TR200103469T2 (tr) Amiloidojenik hastalığının önlenmesi ve tedavisi
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
HUP0500060A2 (hu) Humán VII-es koagulációs faktor polipeptidek
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
MXPA02006679A (es) Composicion farmaceutica.
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
TR200003347T2 (tr) Neisseria meningitidis'denBASB029 polinükleotidleri ve polipeptidler
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
BR0312889A (pt) Polipeptìdeo t20 peguilado
HUP0303167A2 (hu) IB-alfa vérlemezke glikoproteinnel képzett fúziós polipeptidek, továbbá eljárások alkalmazásukra
HUP0400976A2 (hu) VII-es faktor polipeptideket és XI-es faktor polipeptideket tartalmazó gyógyszerészeti összetételek
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
WO2004056384A3 (en) Use of factor vii polypeptides for preventing formation of inhibitors to blood coagulation factor viii and ix
WO2001051511A3 (de) Rekombinante herstellung von humanen histon 1-subtypen sowie deren verwendung für therapeutische zwecke
HUP0203251A2 (hu) Az apolipoprotein B-100 epitópját utánzó peptidek, ezeknek megfelelő konkatemér és módosított peptidek és ezeket tartalmazó vakcinakészítmények
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
ATE283279T1 (de) Therapeutische inhaltsstoffe
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
SE9703287D0 (sv) Peptides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties